Synergy CHC (SNYR) Competitors $2.36 -0.05 (-2.07%) As of 02:54 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SNYR vs. IPA, ORMP, OVID, OKYO, VXRT, ATRA, QNCX, WHWK, KALA, and CVMShould you be buying Synergy CHC stock or one of its competitors? The main competitors of Synergy CHC include ImmunoPrecise Antibodies (IPA), Oramed Pharmaceuticals (ORMP), Ovid Therapeutics (OVID), OKYO Pharma (OKYO), Vaxart (VXRT), Atara Biotherapeutics (ATRA), Quince Therapeutics (QNCX), Whitehawk Therapeutics (WHWK), KALA BIO (KALA), and CEL-SCI (CVM). These companies are all part of the "pharmaceutical products" industry. Synergy CHC vs. Its Competitors ImmunoPrecise Antibodies Oramed Pharmaceuticals Ovid Therapeutics OKYO Pharma Vaxart Atara Biotherapeutics Quince Therapeutics Whitehawk Therapeutics KALA BIO CEL-SCI Synergy CHC (NASDAQ:SNYR) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk. Do insiders and institutionals hold more shares of SNYR or IPA? 6.7% of ImmunoPrecise Antibodies shares are held by institutional investors. 56.6% of Synergy CHC shares are held by insiders. Comparatively, 6.8% of ImmunoPrecise Antibodies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts recommend SNYR or IPA? Synergy CHC presently has a consensus price target of $10.00, suggesting a potential upside of 323.73%. ImmunoPrecise Antibodies has a consensus price target of $4.00, suggesting a potential upside of 90.93%. Given Synergy CHC's stronger consensus rating and higher possible upside, equities analysts clearly believe Synergy CHC is more favorable than ImmunoPrecise Antibodies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50ImmunoPrecise Antibodies 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, SNYR or IPA? Synergy CHC has higher revenue and earnings than ImmunoPrecise Antibodies. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC$34.83M0.64$2.12M$0.386.21ImmunoPrecise Antibodies$24.52M3.94-$21.69M-$0.68-3.08 Does the media favor SNYR or IPA? In the previous week, ImmunoPrecise Antibodies had 2 more articles in the media than Synergy CHC. MarketBeat recorded 4 mentions for ImmunoPrecise Antibodies and 2 mentions for Synergy CHC. Synergy CHC's average media sentiment score of 0.22 beat ImmunoPrecise Antibodies' score of 0.20 indicating that Synergy CHC is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synergy CHC 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunoPrecise Antibodies 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is SNYR or IPA more profitable? Synergy CHC has a net margin of 10.02% compared to ImmunoPrecise Antibodies' net margin of -122.10%. Synergy CHC's return on equity of -18.56% beat ImmunoPrecise Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHC10.02% -18.56% 20.28% ImmunoPrecise Antibodies -122.10%-40.62%-22.19% SummarySynergy CHC beats ImmunoPrecise Antibodies on 12 of the 16 factors compared between the two stocks. Get Synergy CHC News Delivered to You Automatically Sign up to receive the latest news and ratings for SNYR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNYR vs. The Competition Export to ExcelMetricSynergy CHCCONS PD IndustryStaples SectorNASDAQ ExchangeMarket Cap$22.28M$32.85B$15.93B$9.89BDividend YieldN/A2.58%3.03%4.49%P/E Ratio6.2139.7718.4426.58Price / Sales0.641.7547.61162.32Price / Cash9.1016.3814.8828.92Price / Book-1.807.325.816.52Net Income$2.12M$1.23B$682.79M$266.21M7 Day Performance11.32%-1.87%-1.45%-0.96%1 Month Performance-32.76%4.95%0.02%3.61%1 Year PerformanceN/A19.53%1.69%24.03% Synergy CHC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYRSynergy CHC4.3422 of 5 stars$2.36-2.1%$10.00+323.7%N/A$22.28M$34.83M6.2140IPAImmunoPrecise Antibodies2.7205 of 5 stars$1.93-18.6%$4.00+107.3%+195.7%$89.07M$17.59M-2.8480Short Interest ↓Gap UpORMPOramed Pharmaceuticals1.1392 of 5 stars$2.15-2.3%N/A-8.7%$88.15M$1.34M-6.1410Positive NewsOVIDOvid Therapeutics4.3825 of 5 stars$1.23-3.9%$3.10+152.0%+22.0%$87.47M$570K-2.3260Gap DownOKYOOKYO Pharma3.2378 of 5 stars$2.32-1.3%$7.00+201.7%+97.4%$87.26MN/A0.007News CoveragePositive NewsShort Interest ↓VXRTVaxart2.4166 of 5 stars$0.38-2.9%$2.00+428.4%-54.2%$86.65M$47.40M-1.40120News CoverageGap DownATRAAtara Biotherapeutics4.5111 of 5 stars$12.34+2.4%$21.00+70.2%+85.5%$86.63M$128.94M-28.70330News CoverageQNCXQuince Therapeutics3.725 of 5 stars$1.60flat$8.14+408.9%+132.3%$85.94MN/A-1.4760Positive NewsWHWKWhitehawk TherapeuticsN/A$1.82+0.8%N/AN/A$85.77M$21.60M-30.3340Gap DownKALAKALA BIO2.8405 of 5 stars$12.19+8.6%$13.00+6.6%+148.1%$85.57M$3.89M-1.8030News CoverageAnalyst UpgradeHigh Trading VolumeCVMCEL-SCI0.4026 of 5 stars$12.16+16.6%N/A-63.1%$83.69MN/A-25.3343Short Interest ↑Gap Up Related Companies and Tools Related Companies ImmunoPrecise Antibodies Competitors Oramed Pharmaceuticals Competitors Ovid Therapeutics Competitors OKYO Pharma Competitors Vaxart Competitors Atara Biotherapeutics Competitors Quince Therapeutics Competitors Whitehawk Therapeutics Competitors KALA BIO Competitors CEL-SCI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNYR) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synergy CHC Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synergy CHC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
